Character Biosciences

Character Biosciences is a precision medicine company focused on age-related and progressive polygenic diseases, particularly in ophthalmology and macular degeneration. Founded in 2019 and rebranded in 2022, the company utilizes a data-driven approach to classify diseases into genetic subtypes, enabling the development of targeted therapies. Headquartered in New Jersey, Character Biosciences collaborates with patients, healthcare providers, and researchers to create detailed patient cohorts for clinical genomic research and drug discovery. The company has raised $93 million in funding to support its initiatives. Its precision medicine platform combines human genetics, clinical data, and machine learning to identify disease subtypes and therapeutic targets. Character Biosciences is advancing two key products: CTX203, a lipid regulator for high-risk intermediate age-related macular degeneration, and CTX114, a complement inhibitor for geographic atrophy in dry AMD, both moving toward Phase I trials. The company emphasizes patient impact, ethical transparency, and diversity in its clinical research efforts.